From: Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
Characteristics | Control group (N = 510) | Isoniazid group (N = 514) | Ethambutol group (N = 524) | All patients (N = 1548) | ||||
---|---|---|---|---|---|---|---|---|
Sex | Male (N = 356) | Female (N = 154) | Male (N = 351) | Female (N = 163) | Male (N = 369) | Female (N = 155) | Male (N = 1076) | Female (N = 472) |
Age group* | ||||||||
≤ 30 years | 155 (44) | 89 (58) | 170 (48) | 84 (52) | 161 (44) | 80 (52) | 486 (45) | 253 (54) |
> 30 years | 201 (56) | 65 (42) | 181 (52) | 79 (48) | 208 (56) | 75 (48) | 590 (55) | 219 (46) |
Weight group* | ||||||||
< 40 kg | 14 (4) | 36 (23) | 14 (4) | 30 (18) | 29 (8) | 29 (19) | 57 (5) | 95 (20) |
40–45 kg | 45 (13) | 35 (23) | 54 (15) | 36 (22) | 54 (15) | 28 (18) | 153 (14) | 99 (21) |
> 45–55 kg | 163 (46) | 43 (28) | 159 (45) | 51 (31) | 149 (40) | 55 (35) | 471 (44) | 149 (32) |
> 55 kg | 134 (38) | 40 (26) | 124 (35) | 46 (28) | 137 (37) | 43 (28) | 395 (37) | 129 (27) |
BMI | ||||||||
< 18.5 | 196 (55) | 71 (46) | 199 (57) | 73 (45) | 211 (57) | 64 (41) | 606 (56) | 208 (44) |
≥ 18.5 | 160 (45) | 83 (54) | 152 (43) | 90 (55) | 158 (43) | 91 (59) | 470 (44) | 264 (56) |
Race or ethnic group*‡ | ||||||||
Black | 171 (48) | 67 (44) | 150 (43) | 60 (37) | 173 (47) | 64 (41) | 494 (46) | 191 (40) |
Asian | 109 (31) | 51 (33) | 107 (30) | 47 (29) | 119 (32) | 42 (27) | 335 (31) | 140 (30) |
Mixed race or other | 76 (21) | 36 (23) | 94 (27) | 56 (34) | 77 (21) | 49 (32) | 247 (23) | 141 (30) |
Smoking status* | ||||||||
Never | 133 (37) | 113 (73) | 121 (34) | 110 (67) | 127 (34) | 103 (66) | 381 (35) | 326 (69) |
Past | 105 (29) | 14 (9) | 100 (28) | 11 (7) | 117 (32) | 17 (11) | 322 (30) | 42 (9) |
Current | 118 (33) | 27 (18) | 130 (37) | 42 (26) | 125 (34) | 35 (23) | 373 (35) | 104 (22) |
HIV positivity* | 21 (6) | 17 (11) | 23 (7) | 14 (9) | 17 (5) | 18 (12) | 61 (6) | 49 (10) |
Cavitation*ǁ | 268 (75) | 100 (65) | 244 (70) | 113 (69) | 264 (72) | 103 (66) | 776 (72) | 316 (67) |
Area of lung involvement (%, (SD)) | 21.5 (12.5) | 20.1 (12.4) | 20.9 (13.1) | 19.2 (12.1) | 20.9 (12.2) | 19.7 (11.0) | 21.1 (12.6) | 19.7 (11.9) |
Smear grading | ||||||||
Neg | 14 (4) | 7 (5) | 14 (4) | 5 (3) | 17 (5) | 7 (5) | 45 (4) | 19 (4) |
1+ | 32 (9) | 15 (10) | 24 (7) | 17 (10) | 25 (7) | 14 (9) | 81 (8) | 46 (10) |
2+ | 43 (12) | 19 (12) | 52 (15) | 26 (16) | 62 (17) | 22 (14) | 157 (15) | 67 (14) |
3+ | 86 (24) | 42 (27) | 79 (23) | 37 (23) | 82 (22) | 32 (21) | 247 (23) | 111 (24) |
4+ | 181 (51) | 71 (46) | 182 (52) | 78 (48) | 183 (50) | 80 (52) | 546 (51) | 229 (49) |
LJ | ||||||||
Positive | 283 (79) | 117 (76) | 277 (79) | 137 (84) | 294 (80) | 132 (85) | 854 (81) | 386 (82) |
Negative | 33 (9) | 14 (9) | 25 (7) | 12 (7) | 31 (8) | 4 (3) | 89 (8) | 30 (6) |
Contaminated | 29 (8) | 16 (10) | 38 (11) | 14 (9) | 33 (9) | 16 (10) | 100 (9) | 46 (10) |
Indeterminate | 11 (3) | 7 (5) | 11 (3) | 0 (0) | 11 (3) | 3 (2) | 33 (3) | 10 (2) |
TTD (median [IQR]) | 14 [14–21] | 14 [14–21] | 14 [14–25] | 14 [14–21] | 21 [14–28] | 14 [14–21] | 14 [14–21] | 14 [14–21] |
MGIT | ||||||||
Positive | 329 (92) | 141 (92) | 319 (93) | 157 (96) | 332 (90) | 147 (95) | 980 (93) | 445 (94) |
Negative | 5 (1) | 2 (1) | 4 (1) | 0 (0) | 7 (2) | 2 (1) | 16 (2) | 4 (1) |
Contaminated | 11 (3) | 4 (3) | 10 (3) | 6 (4) | 15 (4) | 3 (2) | 36 (3) | 13 (3) |
False positive | 2 (1) | 0 (0) | 5 (1) | 0 (0) | 4 (1) | 0 (0) | 11 (1) | 0 (0) |
Indeterminate | 9 (3) | 7 (5) | 13 (4) | 0 (0) | 11 (3) | 3 (2) | 13 (1) | 10 (2) |
TTP (median [IQR]) | 4.81 [3.71–6.66] | 5.13 [3.79–6.79] | 4.92 [3.70–6.39] | 5.04 [4.03–6.43] | 4.83 [3.67–6.58] | 4.73 [3.70–6.50] | 4.83 [3.71–6.50] | 5.04 [3.88–6.46] |